Insight into Flibanserin, Women’s Libido Drug

Posted on Jun 5, 2015

OLYMPUS DIGITAL CAMERA

Risa Kagan, M.D., is nationally recognized for her work in the field of menopause.

Alta Bates Summit and Sutter East Bay Medical Foundation OB/GYN, Risa Kagan, M.D., was  a principal investigator for flibanserin, a women’s libido drug that has taken a step toward FDA approval.

On June 4, the FDA’s joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee determined by an 18 to 6 vote that the benefit/risk profile of flibanserin supports FDA approval of the new drug for treatment of low libido in premenopausal women — if certain risk management options beyond labeling are implemented.

“There are currently no drugs approved for female sexual function (while there are 26 drugs approved for males). With this vote we are one step closer to having an approved option for women,” Kagan says.

“We can have a safety discussion that is well-informed, monitored and updated, as opposed to the quackery and off-label treatments patients currently resort to,” she adds.

Dr. Kagan’s  research was done in conjunction with Alta Bates Summit’s REDI (Jordan Research and Education Institute).

Leave a Reply

Your email address will not be published. Required fields are marked *